Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) presented interim data from its Phase 2 (Study II) clinical study at the American Society of Clinical Oncology (ASCO) Genito Urinary Cancer Symposium via a moderated poster...

February 23, 2023

Markets

Dawson James starts Hillstream at buy; PT $4

Dawson James Securities initiated coverage of Hillstream BioPharma (NASDAQ:HILS) with a “buy” rating and price target of $4. The stock closed at $1.24 on Feb. 21. Hillstream is a preclinical biotechnology company...

February 22, 2023

Developments

SenterCare in pact to bring aging-at-home-safely technology to Japan

Closely-held SenterCare, a member of the Trendlines Group of Israel, and Nozomi MedAlliance established an alliance to bring SenterCare’s advanced aging-at-home-safely technology to the Japanese market. SenterCare has...

February 21, 2023

Developments

IntelGenx receives USPTO notice of allowance for loxapine Orange Book eligible patent

The United States Patent and Trademark Office has granted a notice of allowance for IntelGenx’s (TSX:IGX; OTCQB:IGXT) U.S. patent application entitled, “Loxapine Film Oral Dosage Form.” The film formulation patent...

February 21, 2023

Developments

Theralase named to TSXV 2023 Venture 50

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) was named to the TSX Venture Exchange’s 2023 Venture 50, an annual ranking of top-performing companies from five industry sectors. Theralase was recognized in the clean...

February 21, 2023

Markets

AGP starts CollPlant at buy; PT $22.75

Alliance Global Partners initiated coverage of CollPlant Biotechnologies (NASDAQ:CLGN) with a “buy” rating and price target of $22.75. The stock closed at $11.80 on Feb. 16. CollPlant has developed a proprietary method...

February 17, 2023

Developments

Freedom Holding to acquire Maxim Group for $400-million

Freedom Holding (NASDAQ:FRHC), a multi-national financial services firm, agreed to acquire Maxim Group and its registered investment advisory affiliate, Maxim Financial Advisors, for a combination of cash and common...

February 17, 2023

Markets

Cantor starts Transgene at OW; PT €4

Cantor Fitzgerald launch coverage of France-based Transgene (TNG:PA) with an “overweight” rating and a 12-month price target of €4. The stock was quoted at €2.01 on Feb. 17. “Our constructive view on Transgene stock is...

February 17, 2023

Developments

iBio selects MUC16 as next immuno-oncology target program

iBio (NYSE American:IBIO) selected MUC16 as the target of its latest immuno-oncology program. MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and...

February 17, 2023

Developments

Aravive to present positive updated data at ASCO GU cancer symposium

Aravive (NASDAQ:ARAV) will present updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU)...

February 14, 2023

Developments

Cardiology imaging study urges use of intravascular imaging for PCI guidance

A new review from the American College of Cardiology’s Interventional Council strongly suggests that intracoronary imaging should now be a routine part of clinical practice, as it can be used to assess the lesion prior...

February 14, 2023

Markets

Cantor starts MoonLake at OW; PT $23

Cantor Fitzgerald initiated coverage of MoonLake Immunotherapeutics (NASDAQ:MLTX) with an “overweight” rating and a 12-month price target of $23. The stock closed at $16.30 on Feb. 13. MoonLake has an IL-17A and IL-17F...

February 14, 2023

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Dawson James starts Hillstream at buy; PT $4

SenterCare in pact to bring aging-at-home-safely technology to Japan

IntelGenx receives USPTO notice of allowance for loxapine Orange Book eligible patent

Theralase named to TSXV 2023 Venture 50

AGP starts CollPlant at buy; PT $22.75

Freedom Holding to acquire Maxim Group for $400-million

Cantor starts Transgene at OW; PT €4

iBio selects MUC16 as next immuno-oncology target program

Aravive to present positive updated data at ASCO GU cancer symposium

Cardiology imaging study urges use of intravascular imaging for PCI guidance

Cantor starts MoonLake at OW; PT $23

General

More